ECM
ABUS icon

ExodusPoint Capital Management’s Arbutus Biopharma ABUS Stock Holding History

ExodusPoint Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$106K Sell
23,554
-6,949
-23% -$30.4K ﹤0.01% 1434
2025
Q4 		$147K Sell
30,503
-51,874
-63% -$233K ﹤0.01% 1417
2025
Q3 		$374K Buy
82,377
+1,302
+2% +$4.78K ﹤0.01% 1249
2025
Q2 		$251K Buy
81,075
+1,575
+2% +$5.23K ﹤0.01% 1273
2025
Q1 		$277K Buy
+79,500
New +$265K ﹤0.01% 1246
2021
Q4 		– Sell
-22,184
Closed -$95K – 2116
2021
Q3 		$95K Buy
+22,184
New +$73.9K ﹤0.01% 1913
2021
Q2 		– Sell
-160,048
Closed -$533K – 2271
2021
Q1 		$533K Buy
160,048
+42,570
+36% +$164K 0.01% 1301
2020
Q4 		$417K Buy
117,478
+104,534
+808% +$366K ﹤0.01% 1356
2020
Q3 		$41K Sell
12,944
-4,056
-24% -$12.3K ﹤0.01% 1641
2020
Q2 		$31K Buy
17,000
+3,131
+23% +$5.12K ﹤0.01% 1698
2020
Q1 		$14K Sell
13,869
-22,690
-62% -$61.4K ﹤0.01% 1015
2019
Q4 		$102K Sell
36,559
-3,141
-8% -$5.08K ﹤0.01% 1424
2019
Q3 		$61K Buy
+39,700
New +$68.4K ﹤0.01% 1269

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

ExodusPoint Capital Management's ABUS Position: Q1 2026 in Review

ExodusPoint Capital Management reduced its Arbutus Biopharma (ABUS) stake by 23% in Q1 2026, selling an estimated $30.4K and leaving 23,554 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #1434.

ExodusPoint Capital Management first reported a position in ABUS in Q3 2019 and has held it in 13 quarters since. The position peaked at $533K in Q1 2021. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • ExodusPoint Capital Management held 23,554 shares of Arbutus Biopharma worth $106K as of Q1 2026.
  • ExodusPoint Capital Management sold 6,949 Arbutus Biopharma shares in Q1 2026, an estimated $30.4K.
  • Arbutus Biopharma made up ﹤0.01% of ExodusPoint Capital Management's portfolio in Q1 2026, its #1434 holding.
  • ExodusPoint Capital Management first reported a position in Arbutus Biopharma in Q3 2019 and has held it in 13 quarters since.
  • ExodusPoint Capital Management's Arbutus Biopharma position peaked at $533K in Q1 2021.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.